General Information of This Drug (ID: DMQYLGP)

Drug Name
Levocetirizine   DMQYLGP
Synonyms
(-)-Cetirizine; (-)-Cetirizine Dihydrochloride; (2-(4-((R-p-Chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid; (2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid; (R)-2-(2-(4-((4-Chlorophenyl)(phenyl)methyl)piperazin-1-yl)ethoxy)acetic acid; (R)-Cetirizine dihydrochloride; 6U5EA9RT2O; Acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-; Levocetirizine; Levocetirizine HCl; UNII-6U5EA9RT2O; Xarlin; Xyzal; cetirizine-d4; levocetrizine
Indication
Disease Entry ICD 11 Status REF
Allergic rhinitis CA08.0 Approved [1]
Seasonal allergic rhinitis CA08.01 Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Valsartan + Levocetirizine DC7YLAY Valsartan Diabetic Nephropathies [2]
Montelukast + Levocetirizine DCG8FA3 Montelukast Allergic Rhinitis [3]
------------------------------------------------------------------------------------

References

1 Levocetirizine FDA Label
2 ClinicalTrials.gov (NCT05638880) Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease
3 ClinicalTrials.gov (NCT02551536) Montelukast and Fexofenadine Versus Montelukast and Levocetrizine Combination in Allergic Rhinitis